Picture [iito] Back into Ad 650x80px
Organisation › Details

EryDel S.p.A.

Based in Milan, Italy, EryDel SpA is a biotechnology company specialized in the development of drugs delivered through red blood cells (RBCs) by using a proprietary medical device technology. Its most advanced product, EryDex System (EDS) is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC’s delivery technology for the treatment of other rare diseases. *


Period Start 2013-09-21 existent
Products Industry drug delivery technology (drug formulation technology)
  Industry 2 EryDex
Person Person Benatti, Luca (EryDel 201804 CEO before Newron CEO + Founder)
Region Region Italy_oo
  Country Italy
  Street 36 Via Sasso
  City 61029 Urbino (PU)
  Tel +39-0722-378711
    Address record changed: 2018-07-24
Basic data Employees n. a.
    * Document for �About Section�: EryDel S.p.A.. (4/24/18). "Press Release: EryDel Raises Euro 26.5 Million in Financing. Sofinnova Partners Leads Erydel’s Financing". Bresso.
Record changed: 2018-08-14


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for EryDel S.p.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top